Flora Growth (FLGC) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
2 Feb, 2026Executive summary
Completed accretive acquisitions in Germany (TruHC) and Australia (Australian Vaporizers), and formed a U.S. joint venture with Althea Group Holdings to expand in cannabis and beverage markets.
Launched new products in core brands, including Vessel's Compass Rise and JustCBD's gummies, and expanded distribution in the UK, Israel, and Poland.
Revenue for Q2 2024 was $15.7 million, down from $21.5 million in Q2 2023, mainly due to discontinued unprofitable lines and lower JustCBD sales.
Net loss for Q2 2024 was $2.7 million, a significant improvement from $44.6 million in Q2 2023, driven by lower operating expenses.
Operating expenses and cash used in operations decreased notably, with quarter-end cash of $6.1 million.
Financial highlights
Q2 2024 revenue was $15.7 million; six-month revenue was $33.7 million, down from $40.8 million year-over-year.
Net loss for Q2 2024 was $2.7 million; six-month net loss was $6.0 million, an 88% improvement year-over-year.
Operating expenses for Q2 2024 were $6.7 million, down from $44 million; for six months, $13.0 million, down from $51.7 million.
Adjusted EBITDA loss for Q2 2024 was $2.8 million, improved from $3.9 million; for six months, $4.3 million loss, improved from $4.7 million.
Ended Q2 2024 with $6.1 million in cash and $3.0 million in working capital.
Outlook and guidance
Gross margin is expected to stabilize in the mid-thirties percentage range, with gradual improvement as more profitable lines are added.
Management is focused on cost reductions, operational synergies, and expanding international markets, especially in Germany and Australia.
Near-term revenue growth is anticipated from U.S. beverage initiatives and e-commerce expansion in Germany.
Substantial doubt remains about the ability to continue as a going concern without additional capital; management is evaluating financing alternatives.
Regulation A and ATM offerings provide flexibility for future financing to support business expansion.
Latest events from Flora Growth
- Net loss surged to $119.7M on digital asset losses as the company pivoted to an AI-focused treasury model.FLGC
Q4 202527 Feb 2026 - Q3 revenue dropped and net loss widened, but U.S. and German growth prospects remain.FLGC
Q3 202414 Jan 2026 - Strategic shift to AI and digital assets, with major OG Token holdings and expanded pharma reach.FLGC
Registration Filing8 Jan 2026 - Registering 3.86M shares for resale; proceeds go to investors, not the company.FLGC
Registration Filing16 Dec 2025 - 3.2 million shares registered for resale after acquisition and executive grants; no proceeds to issuer.FLGC
Registration Filing16 Dec 2025 - 3.2 million shares registered for resale; no proceeds to company; global cannabis expansion focus.FLGC
Registration Filing16 Dec 2025 - Shareholders to vote on TruHC acquisition, equity plan, and executive awards amid ongoing losses.FLGC
Proxy Filing2 Dec 2025 - Proxy seeks approval for director elections, equity plan, executive SARs, and TruHC share issuance.FLGC
Proxy Filing2 Dec 2025 - Key votes include director elections, share consolidation, and expanded equity incentives.FLGC
Proxy Filing2 Dec 2025